MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
09/20/18MyoKardia Launches Inaugural MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
08/23/18New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
NASDAQ GS | MYOK (Common Stock)
$63.10 - 1.25
09/21/184:02 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.